Research Programme: Hematopoietic progenitor kinase 1 inhibitors - Cullinan Therapeutics
Latest Information Update: 23 Apr 2024
At a glance
- Originator Cullinan Oncology
- Developer Cullinan Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Apr 2024 Cullinan Oncology is now called Cullinan Therapeutics
- 12 May 2023 Preclinical trials in Cancer in USA (PO) before May 2023
- 12 May 2023 Cullinan Oncology and Icahn School of Medicine at Mount Sinai jointly own one patent family related to compositions comprising compounds which degrade HPK1 and methods of using such compounds therapeutically